Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Other Operating Expenses (2016 - 2024)

Historic Other Operating Expenses for Perspective Therapeutics (CATX) over the last 15 years, with Q4 2024 value amounting to $32000.0.

  • Perspective Therapeutics' Other Operating Expenses rose 4545.45% to $32000.0 in Q4 2024 from the same period last year, while for Sep 2025 it was $32000.0, marking a year-over-year increase of 18205.13%. This contributed to the annual value of -$27000.0 for FY2024, which is N/A changed from last year.
  • Per Perspective Therapeutics' latest filing, its Other Operating Expenses stood at $32000.0 for Q4 2024, which was up 4545.45% from -$61000.0 recorded in Q2 2024.
  • In the past 5 years, Perspective Therapeutics' Other Operating Expenses registered a high of $1.6 million during Q1 2022, and its lowest value of -$13.0 million during Q4 2022.
  • Its 5-year average for Other Operating Expenses is -$2.5 million, with a median of -$2000.0 in 2021.
  • In the last 5 years, Perspective Therapeutics' Other Operating Expenses surged by 8040000.0% in 2020 and then crashed by 113429.7% in 2022.
  • Quarter analysis of 5 years shows Perspective Therapeutics' Other Operating Expenses stood at -$7000.0 in 2020, then surged by 10971.43% to $761000.0 in 2021, then plummeted by 1806.44% to -$13.0 million in 2022, then surged by 100.17% to $22000.0 in 2023, then surged by 45.45% to $32000.0 in 2024.
  • Its Other Operating Expenses was $32000.0 in Q4 2024, compared to -$61000.0 in Q2 2024 and $22000.0 in Q4 2023.